45.67
전일 마감가:
$44.65
열려 있는:
$45.17
하루 거래량:
65,773
Relative Volume:
0.15
시가총액:
$2.26B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-28.33
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
+2.62%
1개월 성능:
+11.28%
6개월 성능:
+2.14%
1년 성능:
+82.79%
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MIRM
Mirum Pharmaceuticals Inc
|
45.71 | 2.18B | 379.25M | -77.34M | -27.87M | -1.6122 |
![]()
ONC
Beone Medicines Ltd Adr
|
256.74 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
448.02 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.49 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
498.49 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-19 | 재개 | H.C. Wainwright | Buy |
2024-04-17 | 개시 | Stifel | Buy |
2023-12-18 | 재확인 | H.C. Wainwright | Buy |
2023-11-20 | 재개 | JP Morgan | Overweight |
2023-11-13 | 개시 | Morgan Stanley | Overweight |
2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
2023-10-17 | 재개 | Evercore ISI | Outperform |
2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
2022-09-01 | 개시 | Citigroup | Buy |
2021-09-20 | 개시 | JP Morgan | Overweight |
2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2020-08-03 | 개시 | H.C. Wainwright | Buy |
2020-07-31 | 개시 | Piper Sandler | Overweight |
2020-06-25 | 개시 | Robert W. Baird | Outperform |
2019-08-12 | 개시 | Citigroup | Buy |
2019-08-12 | 개시 | Evercore ISI | Outperform |
2019-08-12 | 개시 | Guggenheim | Buy |
2019-08-12 | 개시 | ROTH Capital | Buy |
2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Insider Sell: Saira Ramasastry Sells 8,203 Shares of Mirum Pharm - GuruFocus
Mirum Pharmaceuticals director sells shares totaling $377,843 By Investing.com - Investing.com India
Mirum Pharmaceuticals director sells shares totaling $377,843 - Investing.com
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Alagille Syndrome Treatment Market Detailed in New Research ReportMirum Pharmaceuticals, Albireo Pharma - openPR.com
Two Sigma Investments LP Has $5.23 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes - Defense World
What is HC Wainwright’s Estimate for MIRM Q2 Earnings? - Defense World
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - citybiz
Comerica Bank Reduces Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Buy” Rating at HC Wainwright - Defense World
Mirum Pharmaceuticals Names Doug Sheehy New Chief Legal Officer - Bloomberg Law News
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwri - GuruFocus
Mirum Pharmaceuticals (MIRM) Appoints New Chief Legal Officer | - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwright & Co. | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating with Promising Growth Potential | MIRM Stock News - GuruFocus
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $60.64 - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Northern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
FY2025 EPS Estimates for MIRM Raised by Cantor Fitzgerald - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for MIRM - Defense World
JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $76.00 - Defense World
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Nigeria
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):